GD2
Names | |
---|---|
IUPAC name
(2R,4R,5S,6S)-2-[3-[(2S,3S,4R,6S)-6-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-amino-6-carboxy-4-hydroxyoxan-2-yl]-2,3-dihydroxypropoxy]-5-amino-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid
| |
Other names
Ganglioside G2
| |
Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
Properties | |
C74H134N4O32 | |
Molar mass | 1591.882 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans.
The relatively tumor specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T cell receptors.[1]
See also
References
- ^ Wierzbicki, Andrzej; Gil, Margaret; Ciesielski, Michael; Fenstermaker, Robert A.; Kaneko, Yutaro; Rokita, Hanna; Lau, Joseph T.; Kozbor, Danuta (2008). "Immunization with a Mimotope of GD2 Ganglioside Induces CD8+ T Cells That Recognize Cell Adhesion Molecules on Tumor Cells". Journal of Immunology. 181 (9): 6644–6653. doi:10.4049/jimmunol.181.9.6644. PMC 2730120. PMID 18941255.
2. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. Ahmed M, Cheung NK. FEBS Lett. 2014 Jan 21;588(2):288-97
3. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Cheung NK, Dyer MA. Nat Rev Cancer. 2013 Jun;13(6):397-411